Mingaile Drevinskaite, Auguste Kaceniene, Arunas Germanavicius, Giedre Smailyte
{"title":"Increased mortality risk in people with schizophrenia in Lithuania 2001-2020.","authors":"Mingaile Drevinskaite, Auguste Kaceniene, Arunas Germanavicius, Giedre Smailyte","doi":"10.1038/s41537-024-00549-y","DOIUrl":null,"url":null,"abstract":"<p><p>The aim of this study was to assess mortality risk in people with schizophrenia in Lithuania from 2001 and 2020. Cause-specific and all-cause mortality risk among patients with schizophrenia was assessed using a retrospective cohort study design. The cohort identified all patients with schizophrenia diagnosis (ICD-10 code F20) who were admitted to the Vilnius Republican Psychiatric Hospital from 1 January, 2001 to December 31, 2020. Dates of death and emigration were obtained from the Central Population Register. The standardized mortality ratios (SMRs) were calculated by dividing the observed number of deaths among patients with schizophrenia by the expected number of deaths, calculated using the national rates. The final cohort included 7883 patients, with 2458 observed deaths. An increased all-cause mortality risk was found for both sexes (SMR = 1.96; 95% CI 1.88-2.04) compared to the general population. The most common cause-specific mortality risk was found for diseases of the circulatory system (SMR = 2.17; 95% CI 2.05-2.30). Other significant increases in cause-specific mortality risk were observed for infectious diseases, mental and behavioural disorders, diseases of the nervous system and respiratory system, diseases of the genitourinary system, as well as external causes. Patients with schizophrenia do not benefit from the health strategies that have led to reduced mortality in the general population. To close the mortality gap, smoking and alcohol cessation interventions, cardiovascular and cancer screening and monitoring, early diagnosis, and interventions for identified physical diseases should be regarded as imperative.</p>","PeriodicalId":74758,"journal":{"name":"Schizophrenia (Heidelberg, Germany)","volume":"11 1","pages":"7"},"PeriodicalIF":3.0000,"publicationDate":"2025-01-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11739394/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Schizophrenia (Heidelberg, Germany)","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1038/s41537-024-00549-y","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PSYCHIATRY","Score":null,"Total":0}
引用次数: 0
Abstract
The aim of this study was to assess mortality risk in people with schizophrenia in Lithuania from 2001 and 2020. Cause-specific and all-cause mortality risk among patients with schizophrenia was assessed using a retrospective cohort study design. The cohort identified all patients with schizophrenia diagnosis (ICD-10 code F20) who were admitted to the Vilnius Republican Psychiatric Hospital from 1 January, 2001 to December 31, 2020. Dates of death and emigration were obtained from the Central Population Register. The standardized mortality ratios (SMRs) were calculated by dividing the observed number of deaths among patients with schizophrenia by the expected number of deaths, calculated using the national rates. The final cohort included 7883 patients, with 2458 observed deaths. An increased all-cause mortality risk was found for both sexes (SMR = 1.96; 95% CI 1.88-2.04) compared to the general population. The most common cause-specific mortality risk was found for diseases of the circulatory system (SMR = 2.17; 95% CI 2.05-2.30). Other significant increases in cause-specific mortality risk were observed for infectious diseases, mental and behavioural disorders, diseases of the nervous system and respiratory system, diseases of the genitourinary system, as well as external causes. Patients with schizophrenia do not benefit from the health strategies that have led to reduced mortality in the general population. To close the mortality gap, smoking and alcohol cessation interventions, cardiovascular and cancer screening and monitoring, early diagnosis, and interventions for identified physical diseases should be regarded as imperative.
本研究的目的是评估2001年至2020年立陶宛精神分裂症患者的死亡风险。采用回顾性队列研究设计评估精神分裂症患者的病因特异性和全因死亡率风险。该队列确定了2001年1月1日至2020年12月31日在维尔纽斯共和国精神病院住院的所有精神分裂症诊断患者(ICD-10代码F20)。死亡和移民日期可从中央人口登记册获得。标准化死亡率(SMRs)的计算方法是将观察到的精神分裂症患者死亡人数除以使用全国死亡率计算的预期死亡人数。最终队列包括7883例患者,其中2458例观察到死亡。两性全因死亡风险均增加(SMR = 1.96;95% CI 1.88-2.04)。最常见的死因特异性死亡风险是循环系统疾病(SMR = 2.17;95% ci 2.05-2.30)。传染病、精神和行为障碍、神经系统和呼吸系统疾病、泌尿生殖系统疾病以及外部原因导致的特定原因死亡风险显著增加。精神分裂症患者并没有从降低一般人群死亡率的卫生战略中获益。为缩小死亡率差距,应将戒烟和戒酒干预措施、心血管和癌症筛查和监测、早期诊断以及对已查明的身体疾病的干预措施视为当务之急。